Sodium Bicarbonate (Extracellular Buffering Agent)
Sodium Bicarbonate (Extracellular Buffering Agent) is classified under Group A (Evidence-Supported Sports Nutrition & Ergogenic Aids). While specific physiological and performance benefits are supported in peer-reviewed sports nutrition literature, dietary supplements are not universally safe, cannot replace whole-food nutrition, and carry real risks of undeclared prohibited-substance contamination (10–25% of uncertified commercial supplements). Always consult a qualified physician, pharmacist, or accredited sports dietitian.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Sodium Bicarbonate (Extracellular Buffering Agent)
Common Names, Synonyms & Classifications: Sodium Hydrogen Carbonate IP (NaHCO₃); Baking Soda; Systemic Alkalinising Agent
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A05)
2. Pharmacological Class
Extracellular Bicarbonate Buffer & Systemic/Urinary Alkalinising Agent
3. Mechanism of Action
Oral ingestion elevates blood bicarbonate concentration ([HCO₃⁻] by ~4–6 mmol/L) and extracellular pH (+0.05 to +0.08 units). Because the sarcolemmal membrane is relatively impermeable to HCO₃⁻, this steeper transmembrane H⁺ gradient accelerates proton (H⁺) and lactate efflux out of working myocytes via Monocarboxylate Transporters (MCT1 and MCT4), delaying acidosis-induced inhibition of phosphofructokinase (PFK) and cross-bridge cycling.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Transiently induces mild metabolic alkalosis and enhances extracellular buffering capacity. Proven Athletic Performance Benefit: Validated in the 2021 ISSN Position Stand for high-intensity single-bout exercise lasting 30 seconds to 12 minutes (rowing, middle-distance running/swimming, 4-km cycling) and repeated-sprint / combat sports (boxing, judo, wrestling). Unsupported Claims: Can actually degrade performance if acute gastrointestinal distress (vomiting, osmotic diarrhoea) occurs when taken without co-ingested carbohydrate/fluid or enteric protection.
5. Quality of Scientific Evidence
Evidence Assessment: High / Level A Consensus (ISSN Position Stand on Sodium Bicarbonate 2021 & IOC Consensus Statement)
6. Approved Medical Uses (Where Applicable)
Sodium Bicarbonate IP is an NLEM 2022 and IP 2022 official medicine indicated for metabolic acidosis in chronic kidney disease (CKD), severe hyperkalaemia, tricyclic antidepressant/salicylate overdose urinary alkalinisation, and dyspepsia.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
ISSN Position Stand notes that protocols of 0.2–0.3 g/kg body weight taken 60–180 minutes pre-exercise (alongside a carbohydrate meal or in enteric/hydrogel capsules) balance buffering with GI tolerability. Misuse includes ingesting excessive doses (>0.4–0.5 g/kg in a single bolus) causing acute osmotic diarrhoea, or chronic daily overuse causing hypernatraemia and volume overload.
8. Adverse Effects & Serious Safety Risks
High incidence of gastrointestinal distress (gastric distension from CO₂ release, belching, nausea, abdominal cramping, urgent osmotic diarrhoea), hypernatraemia (each gram of NaHCO₃ contains ~274 mg [11.9 mEq] of sodium—a 21 g dose for a 70 kg athlete delivers ~5.75 g of pure sodium!), fluid retention, and transient blood pressure elevation.
9. Contraindications & Precautions
Hypertension, heart failure, oedema, renal impairment, metabolic or respiratory alkalosis, hypocalcaemia (alkalosis lowers ionised calcium and can precipitate tetany), and preeclampsia.
10. Drug Interactions
Urinary alkalinisation (urine pH > 7.5) markedly alters renal tubular clearance of weak acids and bases—accelerating excretion of lithium and salicylates while decreasing renal clearance (increasing toxicity) of weak bases such as pseudoephedrine, flecainide, and quinidine. Alters gastric dissolution of enteric-coated tablets and reduces iron/ketoconazole absorption.
11. Clinical & Laboratory Monitoring Considerations
Trial strictly in training (never for the first time on competition day); account for the high sodium load (~27.4% Na⁺ by weight); monitor blood pressure and serum electrolytes.
12. Dependence, Misuse or Withdrawal Concerns
No dependence. Note that under the WADA Code, using any agent with the intent to alter urine pH/density to tamper with doping control samples is a serious anti-doping rule violation (M2 Tampering).
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Official monograph in Indian Pharmacopoeia (IP 2022) and NLEM 2022 ([10.19]); food-grade sodium bicarbonate is regulated under FSSAI food additive standards.
14. Official WADA Prohibited-List Status
NOT PROHIBITED as an oral buffering substance (However, tampering or attempting to tamper with urine sample integrity during doping control is prohibited under WADA Code Article 2.5 / M2).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026